chloroethyl sulphone | 10038-07-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: chloroethyl sulphone
• 英文别名: bis-(1-chloro-ethyl)-sulfone；1.1'-Dichlor-diaethylsulfon；Bis-(1-chlor-aethyl)-sulfon；chloroethyl sulfone；1-Chloroethyl sulfone；1-chloro-1-(1-chloroethylsulfonyl)ethane
• CAS: 10038-07-0
• 化学式: C₄H₈Cl₂O₂S
• 分子量: 191.078
• InChiKey: YCJARYOIQSUHKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  bis(1-chloroethyl) sulfide 在 过氧化氢苯甲酰 、 氯仿 作用下， 生成 chloroethyl sulphone
  参考文献：
  名称：

  Lewin, Journal fur praktische Chemie (Leipzig 1954), 1930, vol. <2>127, p. 85

  摘要：

  DOI：

文献信息

• [EN] N-OPTIONALLY SUBSTITUTED ARYL-2-OLIGOMER-3-ALKOXYPROPIONAMIDES<br/>[FR] ARYL-2-OLIGOMÈRE-3-ALCOXYPROPIONAMIDES ÉVENTUELLEMENT SUBSTITUÉS EN N
  申请人：NEKTAR THERAPEUTICS

  公开号：WO2012051551A1

  公开（公告）日：2012-04-19

  The invention relates to (among other things) N-optionally substituted aryl- 2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.

  这项发明涉及（其他事项之一）N-选择性取代芳基-2-寡聚体-3-烷氧基丙酰胺和包含其的组合物。根据本发明的化合物，当通过多种给药途径之一给予时，表现出比缺乏寡聚体的相应化合物更多的优点。
• [EN] COMPOSITIONS, DOSAGE FORMS, AND COADMINISTRATION OF AN OPIOID AGONIST COMPOUND AND AN ANALGESIC COMPOUND<br/>[FR] COMPOSITIONS, FORMES GALÉNIQUES ET COADMINISTRATION D'UN COMPOSÉ AGONISTE OPIOÏDE ET D'UN COMPOSÉ ANALGÉSIQUE
  申请人：NEKTAR THERAPEUTICS

  公开号：WO2013070617A1

  公开（公告）日：2013-05-16

  The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.

  本发明一般涉及阿片受体激动剂化合物和镇痛化合物的联合给药。此外，该发明涉及阿片受体激动剂化合物和镇痛化合物的联合给药的剂型，给药阿片受体激动剂化合物和镇痛化合物的方法，包含阿片受体激动剂化合物和镇痛化合物的组合物，包含阿片受体激动剂化合物和镇痛化合物的剂型等。
• [EN] HYDROXYLATED TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES HYDROXYLÉS
  申请人：NEKTAR THERAPEUTICS

  公开号：WO2012079017A1

  公开（公告）日：2012-06-14

  The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer.

  这项发明提供了通过共价连接水溶性寡聚体进行化学修饰的小分子药物。根据本发明的化合物，当通过多种给药途径之一给予时，表现出与未连接水溶性寡聚体的小分子药物不同的特性。
• HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERS
  申请人：Oligasis

  公开号：US20140024776A1

  公开（公告）日：2014-01-23

  The present invention provides multi-armed high MW polymers containing hydrophilic groups and one or more functional agents, and methods of preparing such polymers.

  本发明提供了含有亲水基团和一种或多种功能剂的多臂高分子量聚合物，以及制备这种聚合物的方法。
• Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound
  申请人：Nektar Therapeutics

  公开号：US20170079975A1

  公开（公告）日：2017-03-23

  The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.

  本发明一般涉及阿片受体激动剂化合物和镇痛化合物的联合给药。此外，该发明涉及阿片受体激动剂化合物和镇痛化合物的联合给药剂型，给药阿片受体激动剂化合物和镇痛化合物的方法，包括阿片受体激动剂化合物和镇痛化合物的组合物，包括阿片受体激动剂化合物和镇痛化合物的剂型，等等。

表征谱图